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Over the past ten years signiﬁcant advances have been made in the ﬁelds of gene therapy and tumour immunology, such that
there now exists a considerable body of evidence validating the proof in the principle of gene therapy based cancer vaccines. While
clinical beneﬁt has so far been marginal, data from preclinical and early clinical trials of gene therapy combined with standard
therapies are strongly suggestive of additional beneﬁt. Many reasons have been proposed to explain the paucity of clinical responses
to single agent vaccination strategies including the poor antigenicity of tumour cells and the development of tolerance through
down-regulation of MHC, costimulatory, signal transduction, and other molecules essential for the generation of strong immune
responses. In addition, there is now evidence from animal models that the growing tumour may actively inhibit the host immune
response. Removal of the primary tumour prior to T cell transfer from the spleen of cancer bearing animals, led to eﬀective tumour
cell line speciﬁc immunity in the recipient mouse suggesting that there is an ongoing tumour-host interaction. This model also
illustrates the potential diﬃculties of clinical vaccine trials in patients with advanced stage disease.
INTRODUCTION
In spite of the slow clinical progress, eﬀorts to develop
speciﬁcnontoxiccancertherapiesareincreasingexponen-
tially [1, 2, 3, 4, 5, 6, 7], with the result that over 500 gene
therapy trials have been listed with the FDA to date [8]. A
number of strategies are currently being pursued in can-
cer treatment, aiming to either
(i) enhance immunological rejection of the tumour by
the host,
(ii) decrease tumour cell proliferation and increase cell
cycle control by restoring functions such as p53 and
RB,
(iii) speciﬁcally poison tumour cells according to a 2-
step design; incorporation of an enzyme followed
by administration of a prodrug to be speciﬁcallyac-
tivated in tumour cells harbouring the enzyme, or
(iv) speciﬁcally lyse tumour cells defective in the p53 or
RB pathways using oncolytic viruses which are able
to invade the “defective” tumour cells.
VECTORS (TABLE 1)
Genetic material is optimally transported into host
cells by naturally evolved vectors such as viruses or bac-
teria. Eﬀorts are ongoing to improve on natures’ designs
with increasingly sophisticated vector systems aimed at
allowing prolonged transgene expression at high titre in
the desired cell type whilst remaining nontoxic to the
host [9]. Ideally, vectors should also carry a low risk
of recombination with wild-type pathogens. Currently,
the most promising approaches are based on replication-
c ompet entagentsthatallo weﬃcienttumourpenetration.
Exciting results are anticipated with poxviruses [10, 11]
andwithselectivelyreplicating/targetedadenoviruses[12,
13, 14, 15, 16], although pre-clinical models suggest that
signiﬁcant response rates will only be achieved by combi-
nation with standard therapies.
Poxviruses
Vaccinia virus (VV)-based strategies have been
brought to clinical fruition by a number of diﬀerent
sources [17, 18, 19]. The large potential size (25kb) of the
gene insert, the absence of viral integration into the host
cellular genome, and the excellent immune stimulation
induced by this virus all combine to make it an attractive
candidate for immune based therapy in cancer. Vaccinia
virus infects all cells, however the host immune response
to the vector does not abrogate the tumour immune re-
sponse even following repeated injections. The availabil-
ity of attenuated virus (tk- modiﬁed vaccinia ankara)[ 10]
allows the use of vaccinia in immuno-delicate cancer pa-
tients and there is evidence that this vector enhances im-
munological rejection of the tumour.
In preclinical studies, use of a diversiﬁed immuniza-
tion scheme employing a recombinant vaccinia virus fol-
lowed by recombinant avian pox virus was shown to be
superior to the use of either vector alone in eliciting36 Susy M. Scholl et al 2003:1 (2003)
Table 1. Gene therapy vectors.
Vector
Preexisting Proliferation Genome Pathogenicity Viral Speciﬁcity Limitations (Viral
immunity needed integration persistence titres and safety)
Adenovirus + − No + + + No CAR receptors +
AAV + − ?N o Y e s
Retrovirus − Yes Yes No Yes +
Lentivirus −− Yes No ? Yes CD4 + +
Poxvirus +/−−No No No
Bacterial vvectors,
? − No Antibiotics No Inﬂammation ?
eg, salmonella
Liposomes −− No −− −
Naked DNA −−?N o N o
CEA-speciﬁc T-cell responses. Multiple boosts of ALVAC-
CEA following rV-CEA priming further potentiated the
antitumour eﬀect and CEA speciﬁc T-cell response [20].
Using tetrameric-MHC complexes ex vivo as well as lytic
assays, Estcourt et al [21] were able to show that “prime-
boost” immunization with DNA vaccines and recombi-
nant poxvirus vectors generates high frequencies of cy-
totoxic T lymphocytes (CTL) that recognize target cells
expressing very low levels of the speciﬁc antigen. These
cells persisted for at least 6 months [21]. Harrington et
al [22] quantiﬁed the T-cell responses to both the viral
vector and the insert following infection of mice with
VV expressing a CTL epitope (NP118–126) from lym-
phocytic choriomeningitis virus and demonstrated po-
tent and long-lasting CD8 and CD4 T-cell responses to
the vector peaking at approximately 1 week. These num-
bers decreased to approximately 5 × 105 CD8 T cells (ap-
proximately 5% frequency) and approximately 105 CD4 T
cells (approximately 0.5% frequency), respectively, by day
30, at which levels they were stably maintained for over
300 days. The CD8 T-cell response to the foreign gene
(NP118-126 epitope) was correlated with the response to
thevectorduringallthreephases(expansion,contraction,
and memory) of the T-cell response [22].
Clinical results are still limited to marginal beneﬁt
but the proof of concept is established. Responses to an
intradermally administered live vaccinia virus HPV 16
and 18 E6/E7 gene construct (TA-HPV, Cantab Phar-
maceuticals) were seen in 1/3 of the evaluable patients
with advanced cervical cancer, in 3/12 CIN III volun-
teers, and in 4/29 patients with early invasive cervical can-
cer [19]. A HLA-A∗O201 restricted CD8 T cell response
has also been recorded in the single HLA-A∗O201 patient
whose tumour was shown to be HPV16 positive. Vacci-
nation in breast cancer patients using a poxvirus vector,
MUC1, and IL-2 was well tolerated [23] and did exhibit
evidence of some clinical activity (unpublished results,
2002). Common toxicities included a local skin reaction
at the site of the vaccine, usually of 4–5 days’ duration,
and mild ﬂu-like symptoms of 1–2 days’ duration. Cel-
lular immune response did not correlate with clinical re-
sponse. The presence of a strong immunogenic vector ap-
pears to be important, since vaccination in the absence of
a viral vector (MUC1-KLH conjugate plus QS-21) while
immunogenic (high IgM and IgG antibody titers against
synthetic MUC1), did not result in a cellular immune re-
sponse in breast cancer patients [24].
Adenoviralvectorsandadenoassociatedvectors.
[8,12,25,26]
Adenoviral vectors also have a large transgene capac-
ity,ahighlevelofexpression,andcaninfectalargevariety
of cell types, however limitations are the absence of ade-
noviral receptor expression in certain cell types and the
strong preexisting immunity, which limits transgene ex-
pression. In this regard, a direct relationship between low
susceptibility of tumours to adenovirus injections and the
absence of CAR (Coxsackie adenovirus receptor) expres-
sion on tumour cells has been demonstrated.
Ongoing preclinical emphasis is on designing im-
proved, better targeted, and infectivity-enhanced aden-
oviral vectors. Since CAR deﬁciency in tumours clearly
limits current adenovirus-based therapies, the tropism
has been altered through genetic modiﬁcation of the ade-
novirus capsid by mutating critical residues in the ﬁbre
knob [1] such that tumour cells can be infected via CAR
independent mechanisms [27]. Double mutant AdV ad-
ditionally lacking the integrin-binding penton base RGD
motif were shown to eﬃciently target epidermal growth
factor receptor or epithelial cell adhesion molecules, de-
pending on the choice of the bispeciﬁc linker, result-
ing in a relative glioma/normal brain transduction ratio
of 60 times that achieved with native AdV. Adenovirus-
mediated IFN-γR gene transfer was shown to be eﬀective2003:1 (2003) Gene Therapy Applications to Cancer Treatment 37
in augmenting the biological activity of IFN-γ,as t r a t e g y
which should be useful in studying other applications of
cytokine receptor-based gene therapy for cancer [28]. Re-
garding the transfer of p53, Ad5CMV-p53-infected cells
underwent apoptosis, and cell growth was greatly sup-
pressed. Ad5CMV-p53 treatment signiﬁcantly reduced
the volumes of established subcutaneous tumors in vivo
[29]. In another model using stably transfected mam-
mary carcinoma cells, a dominant negative (DN) mutant
of EGFR, (EGFR-CD533) could act as a potent inhibitor
of EGFR (epithelial growth factor receptor) and its cyto-
protective signaling after exposure to ionizing radiation.
In a genetic approach, using replication-incompetent
adenovirus-mediated transfer of EGFR-CD533, the vec-
tor was able to enhance the radiosensitivity in vitro of
representative cell lines [30]. Adenovirus-mediated ex-
pression of dominant negative-estrogen receptor-induced
apoptosis in breast cancer cells and regression of tumors
in nude mice [31]. In a diﬀerent approach, the antisense
RNA transcript of the E6 and E7 genes of human papil-
lomavirus (HPV) 16 were transfected into cervical cancer
cells harbouring HPV 16, via a recombinant adenoviral
vector, Ad5CMV-HPV 16 AS. Expression of these genes
suppressed greatly the growth of the Ad5CMV-HPV 16
anti-sense infected cells [32]. A rapid induction of cyto-
toxic T-cell response against cervical cancer cells by hu-
man papillomavirus type 16 E6 antigen gene delivery into
human dendritic cells was also demonstrated using an
adeno-associated virus vector [33].
Clinicalresults
The majority of patients who have been treated with
adenovirus vectors received them with the aim of replac-
ing defective genes, in particular p53, however, thus far
clinical eﬃcacy has been limited [34]. Testing by PCR for
adenovirus shedding in body ﬂuids of NSCLC patients
injected intratumorally with adenoviral vectors at doses
of 107–109 plaque forming units, revealed detectable vi-
ral genome for up to 90 days after injection. Screening of
the clinical staﬀ proved consistently negative and did not
provokeariseinantivirusantibodytitres.(EscudierB,In-
stitut Gustave Roussy, personal communication, NDDO
meeting, Valencia, 2001, oral presentation.) Novel strate-
gies that exploit our knowledge of the function and regu-
lation of p53 are being actively investigated [35, 36, 37].
Intravesical instillation of Adenovirus p53 (SCH 5850)
combined with a transduction-enhancing agent is safe,
feasible, and biologically active in patients with bladder
cancer[38].DirectbronchoscopicinjectionofAdp53into
endobronchial NSCLC is safe and with acceptable levels
of toxicity. Initial clinical results demonstrating relief of
airway obstruction warrant further clinical investigation
[39].
Conditionallyreplicativeadenovirusvectorswith
oncolyticpotential[14,15,16,40,41,42,43]
While overall approximately 50% of tumour cells are
defective in the p53 pathway, it is estimated that one hun-
dred percent of tumour cells present one of several defects
in the Rb pathway, the most prevalent being p16 muta-
tions, cyclin D ampliﬁcation, HPV E7 overexpression, or
a defective Rb expression itself.
Preclinicalstudies
The cumulated deletions of two E1B-gene fragments
(E1B 19K and E1B 55K) in Adl 118, engineered by Ra-
mon and Cajal [42] resulted in clear cytopathic eﬀects
in most human cancer cell lines. Intravenous injection of
this conditionally replicative adenovirus, in an adjuvant
situation after excision of the primary tumour, reduced
metastatic disease and could eventually be seen as a strat-
egy to prevent tumour metastasis in high risk breast carci-
nomas. These results were improved on with concomitant
useofchemotherapy.Anotherpotentadenovirus,(ONYX
411,carryinganE1AmutationintheRbbindingdomain)
was signiﬁcantly superior to ONYX 015 in all models.
The E1A gene of ONYX 411 is not complexed by Rb (if
Rb is still expressed) allowing the virus to replicate even
in the presence of Rb. Tumour cells have high levels of
free E2F and therefore genes that have E2F responsive ele-
ments (E1A, TS, TK, dhfr, E2F itself etc.) should be more
highly expressed in tumour cells. High E2F levels in tu-
mour cells will also drive viral E1A expression allowing
eﬀective tumour cell kill by the virus. Similar oncolytic
adenoviruses with selectivity for Rb pathways but without
the CR2 mutation are also under development. Another
strategyis toutilize tumourselective promoters tocontrol
early viral gene expression. Insertion of the E3 region en-
hances selectivity in tumour cell killing. E3 is composed
of a series of genes involved in evasion of immune cell
control, decrease in host cell MHC, Fas, and TNF expres-
sion and gives a consistent better tumour cell to normal
cell kill-ratio. The eﬃcacy of these new vectors has been
shown in xenograft models following intratumour injec-
tion. Another recombinant adenovirus vector in which
p53-dependent expression of a fusion protein (E2F-Rb)
selectively attenuated viralreplication in normal cells, was
further modiﬁed by insertion of the viral late promoter
(MLP) in the E3 region with the aim of driving overex-
pression of Ad5-E3 11.6K protein, thereby increasing cy-
totoxicity in tumour cells, while decreasing cytotoxicity
in normal cells. Selective targeting could be achieved by
Ad5-Delta 24RGD, an adenovirus selectively replication-
competent in cells defective in the Rb/p16 pathway, such
as ovarian cancer cells. The ﬁber of Ad5-Delta 24RGD
contains an integrin binding RGD-4C motif, allowing
Coxsackie adenovirus receptor-independent infection of
cancer cells [44].
Clinicalresults
Over 230 cancer patients have been treated to date
with the dl-1520 (ONYX-015 [15]) a replication-selective
adenovirus. Kirn recently conﬁrmed excellent tolerance
using various injection routes, and documented repro-
ducible evidence of viral replication. Tumour regression38 Susy M. Scholl et al 2003:1 (2003)
was seen following treatment with single agent therapy
in H&N cancer patients (15–20%) but not in other tu-
mours. An early clinical trial of intraperitoneal delivery,
eﬃcacious in nude mouse-human ovarian carcinomato-
sis xenografts, showed no major toxicity without clinical
response [16].
Othervectorsystems
Reovirus is an ubiquitous and relatively benign virus
which may infect cells of the upper respiratory and GI
tracts of humans, but is usually asymptomatic. Based on
theﬁndingthatcellsbecomehighlysusceptibletoreovirus
upontransformationwithoncogenesintheRassignalling
pathway, administration of reovirus in cancer bearing
animals conﬁrmed a speciﬁc antitumour activity which
could be enhanced by combination with chemotherapy
and immune suppressive drugs. In vivo studies of re-
ovirus therapy revealed that viral administration caused
tumour regression in an MDA-MB-435S mammary fat
pad model in severe combined immunodeﬁcient mice
[45].
Evidence of antitumour activity of the G207 herpes-
virus vector in a phase I study of malignant glioma was
shown by MRI (magnetic resonance imaging). This vec-
tor was also shown to be nerve-sparing [46]. Preclini-
cal evaluation showed increased eﬃcacy when adminis-
tered in association with either radiotherapy, Cisplatin, or
cytokines such as IL-12, GM-CSF, or the costimulatory
molecule B7.1 [47, 48, 49].
VNP 2009, an attenuated and genetically modiﬁed
strain of Salmonella typhimurium showed tropism for
t u m o u rc e l l sa sw e l la sa n t i t u m o u ra c t i v i t yi nd o g s
with melanoma, rhabdo-myosarcoma or ﬁbro-sarcoma
50. Shiga toxin B subunit has become a powerful tool
to study retrograde transport between the plasma mem-
brane and the endoplasmic reticulum and may be used
for tumour antigen insertion and presentation by anti-
gen presenting cells [50]. Retroviral vectors are often
favoured for GPAT (gene prodrug-activated therapy),
their advantages being their simple genome, the avail-
ability of AZT, and their mode of transmission which
prevents epidemic outbreak. So far, tumour eradication
has been obtained in vivo only when replicative, but
not defective, vector systems were used to transfer a
suicide gene 51. Both retroviral and lentiviral vectors
were shown to be able to eﬃciently transduce cycling
hepatocarcinoma cell lines in vitro. Following cell cy-
cle arrest, transduction eﬃcacy remained the same for
lentiviral vectors while it decreased by 80% for retro-
viral vectors. The CMV promoter allowed a stronger
transgene expression than the PGK promoter, but ex-
pression rapidly decreased with time due to promoter
silencing [51]. Liver failure which occurred following
TK expression in nontumour cells, emphasized the need
to target the expression of the tk gene to tumor cells
using a hepatoma-speciﬁc promoter such as AFP pro-
moter.
RECOMBINANT STRATEGIES OF INTEREST
Tumourantigens
Many clinical trials in cancer are designed to enhance
immune responsiveness of the host against the so-called
tumour antigens. The advantage of using viral strategies
to transfer tumour antigens is the potential to deliver the
full length genetic information of a protein allowing it to
be processed in accordance with the patients MHC type.
Tumour antigens fall into three main categories.
The ﬁrst are those coded by viral genomes [54, 55].
In principle, these are attractive targets for immunother-
apeutic attack [56, 57, 58], since the cells capable of
responding to these antigens should not have been re-
moved from the repertoire by central tolerance-inducing
mechanisms. The immune response to these exogenously
coded antigens should be vigorous; therefore interfer-
ence by other factors (such as peripheral tolerance or es-
capemechanisms)istheoreticallyminimal.Thesuccessof
therapy directed at EBV in transplant patients and HPV
in cervical cancer patients suggest that under ideal cir-
cumstances, this type of response can indeed be eﬀective
[33, 59].
The second category of antigens are self antigens al-
tered by genetic changes and rendered more visible by
overexpression.Most,ifnotall,tumoursaccumulatemul-
tiple mutations during the process of malignant transfor-
mation and provide treatment targets. Another type of al-
tered self-antigen is exempliﬁed by MUC1, where the al-
tered pattern is caused by genetic changes aﬀecting glyco-
sylation. Just how distinct these neo-epitopes of MUC1
are, however, is called into question by evidence that
most serologically detected epitopes on tumour mucins
are equally seen in the lactating breast. In practice, there is
alittleﬁrmevidenceforthedevelopmentofhighfrequen-
cies of MUC1-reactive T cells in tumour bearing patients
or even in those immunized with MUC1 [60]. Neverthe-
less, the overexpression of MUC1 by tumour cells and ev-
idence of the generation of MUC1-speciﬁc T cells in re-
sponse to vaccination [61, 62] suggest that this may be a
good tumour antigen. Clinical activity has been seen with
poxviral vectors carrying MUC1 (unpublished results,
2002). Poxvirus-based vaccines can reproducibly generate
T-cell responses to tumours expressing CEA or PSA [63].
Disease stabilization has been seen in up to 37% of pa-
tients treated with these vaccines [64]. A phase III trial of
ALVACCEAB7.1incoloncancerisunderdiscussion[65].
Many clinical trials are ongoing in the prostate cancer
ﬁeld, the antigenic proteins to be expressed and presented
to the immune system being PSA or PSMA [18]a sw e l l
as MUC1. Selecting an appropriate therapeutic gene and
vector system to carry the gene driven by a tissue speciﬁc
promoter such as the PSA promoter (PSAP) in prostate
cancer may be important [66, 67, 68]. Trials with complex
designs,alternatingvectors(prime-boost)[20,21,22,69],
and associating immune modulating agents with classical
therapies are ongoing.2003:1 (2003) Gene Therapy Applications to Cancer Treatment 39
The remaining category of tumour antigens, origi-
nallydescribedbyBoonandcolleagues,areunalteredself-
antigens[70,71]withanexpressionproﬁlelimitedtospe-
ciﬁc tissues at certain times in development.
Immunemodulatoryagents
IL-12. In his introductory session at the NDDO meet-
ing in Valencia, Woo [72] focused on preclinical mod-
els using various combinations of immuno-modulatory
gene therapy for cancer. Following intrahepatic implan-
tation of colon or breast carcinoma cells in syngeneic
Balb/c mice, intratumour treatment with a recombinant
adenovirus expressing murine IL-12 was followed by ex-
pression of very high IL-12 (25000pg/ml) and Interferon
gamma (6000pg/ml) titres at the tumour site as well
as tumour rejection and long term survival. This IL-12-
dependent antitumour activity was shown to be medi-
ated by NK cells, despite the fact that these tumours were
MHC class-I-positive [73]. The NK antitumour response
could be complemented through ligation of the 4-1BB re-
ceptor by an agonistic monoclonal antibody leading to
long-term tumour-free survival in over 80% of the ani-
mals [74]. This in turn was associated with resolution of
pre-established metastases in the lung (distant site) and
was T cell-mediated [72]. A clinical trial using an IL-12
expression vector in patients with metastatic lesions from
breast and colon cancer has been authorised by the FDA
and is awaiting the GMP product. In animal models, the
autoradiographic imaging of I [133]-labelled viral vector
showed maximal bio-distribution in the injected tumour
site with only low levels of activity in normal liver, pos-
sibly related to leakage to bile ducts through the needle
puncture site.
IL-2 has a proven record of improving cancer vac-
cinations by expanding T cells [1]. DNA-lipid complex
encoding the interleukin 2 (IL-2) gene (Leuvectin; Vical,
San Diego, Calif) administered intraprostatically into the
hypo-echogenic tumour lesion showed evidence of clini-
caleﬃciencybasedonanincreaseintheintensityofT-cell
inﬁltration seen on immunohistochemical analysis of tis-
sue samples from injected tumor sites and on increased
proliferation rates of peripheral blood lymphocytes. Fur-
thermore, transient decreases in serum prostate-speciﬁc
antigen (PSA) were seen in 16 of 24 responding patients
[75]. Established RM11-PSA tumors ranging in size from
500 to 1,000mm3 were eﬃciently eliminated if Ad5-PSA
(adenovirus-5)primingwasfollowed7dayslaterbyintra-
tumoral injection of recombinant canarypox viruses (AL-
VAC) encoding interleukin-12 (IL-12), IL-2, and tumor
necrosis factor-alpha. This data demonstrates the util-
ity of an Ad5-PSA vaccine combined with cytokine gene
delivery to eliminate large established tumours refrac-
tory to other intervention [76]. Intratumoral treatment
of nude mice with vaccinia virus (VV) expressing inter-
leukin 2 (IL-2) or IL-12 signiﬁcantly inhibited tumour
growth, however there was signiﬁcant associated toxic-
ity [77].Afterfourvaccinations withcytokine-transduced
melanoma cells, antibodies (Abs) against vaccinating and
autologous melanoma cells were generated in 62% of pa-
tients. These ﬁndings demonstrate that the identiﬁcation
and titration of alloreactive Ab helps to monitor the ex-
tent of immunization against cellular vaccines, while the
induction of Ab reactive to antigens shared between vac-
cinating and autologous melanoma cells may contribute
to their therapeutic eﬃcacy [78]. The role of cytokines
such as GM-CSF and IL-2 in the generation of antitu-
mour immune responses was further demonstrated by
their use in association with poxvirus vaccines. While rV-
CEA was eﬀective in priming the immune system, avipox-
CEA could be given up to eight times with continued
increases in CEA T-cell precursors, however further in-
creases in CEA-speciﬁc T-cell precursors were seen when
local granulocyte-macrophage colony-stimulating factor
(GM-CSF) and low-dose interleukin (IL)-2 were given
with subsequent vaccinations [79].
Targeted adenoviral transduction to activate cuta-
neous dendritic cells, was achieved by complexing virus
toabi-speciﬁcantibody, therebyneutralizingthevirusre-
ceptor binding site as well as agonistically binding to CD40
[80]. This resulted in a more selective insitu transduction
of CD1a+ dermal dendritic cells (DC) in a human skin
explant model. DC’s were shown to prime speciﬁc CTL
more eﬃciently in vitro in an autologous restimulation
protocol employing HER-2/neu as the model tumour tar-
get.However,withaslittleas3–10%oftumourcellsuper-
natant even CD40-targeted CTL had a reduced eﬃciency
in the cancer situation. DC diﬀerentiation was hampered
and cells retained the CD14+ phenotype, an eﬀect par-
tially reversible by GM-CSF treatment. Similarly, in an or-
thotopic hepatocellular carcinoma model (HCC) in the
rat, tumorigenicity could be abrogated by prior transfec-
tion with an adenoviral vector carrying the murine CD40
ligand [81, 82]. Tumour rejection was associated with a
peak of IL-12 release on day 5 (> 700pg/ml) and was
CD8+ Tcelldependent.Animalsdevelopedprotectiveim-
munity. Toxicity consisted of a mild increase in ALT levels
withaminorinﬁltrationoflymphocytesintonormalliver.
IP10. Synergy between IL-12 and the interferon
gamma inducible protein IP10 in cancer treatment was
shown using a CT26 tumour model [83]. A one hundred
percent eradication of both injected malignant hepatic
nodules and distant tumour nodules could be achieved
through co-injection of the adenoviral vectors carrying
IL-12 and IP10. Antitumour activity was greatly dimin-
ishedbysimultaneousinvivodepletionofCD4andCD8+
T-cells. The use of the vector carrying IP10 alone or IP10
together with the IV adoptive transfer of antitumour T
lymphocytes only eradicated tumour in 35% of cases.
Blockade of both the CD40-CD40L and CD80/CD86-
CD28 costimulatory pathways represents a strategy to in-
hibit the immune response against Adenovirus vectors
[84]. The CD80/CD86-CD28 costimulatory pathway can
be eﬀectively inhibited by a (stimulatory) CTLA4 fusion
protein[84].Theoppositeisdesirableincancertreatment40 Susy M. Scholl et al 2003:1 (2003)
and the co-stimulatory pathway can be activated through
blockade of CTLA4 and/or transfer of CD80/CD86 [85,
86]. In early stage clinical trials, the addition of B7.1
to virus-based vaccines showed some improvement in
immunological response and in the number of patients
with stable disease following vaccination against tumour-
associated antigens [65]. ALVAC-CEA B7.1 alone (n =
30) or with GM-CSF (n = 30) was also administered
to patients with advanced CEA-expressing tumors to de-
termine whether the addition of the adjuvant GM-CSF
could enhance induction of CEA-speciﬁc T cells [87].
All of the patients had evidence of leukocytic inﬁltration
and CEA expression in vaccine biopsy sites. In the pa-
tients receiving GM-CSF, inﬁltration by leukocytes but
not lymphocytes was greater. Designs of increasing com-
plexity are being currently explored [88]. A diversiﬁed
prime and boost strategy using a prime with a recom-
binant vaccinia vector expressing CEA and the triad of
costimulatory molecules (designated rV-CEA/TRICOM)
and a boost with rF-CEA/TRICOM was more potent in
inducing CEA-speciﬁc T-cell responses than the repeated
use of rF-CEA/TRICOM alone. The addition of GM-
CSF-enhanced CEA-speciﬁc T-cell responses. These stud-
ies demonstrate that the use of cytokines and diversiﬁed
prime and boost regimens can be combined with the use
of recombinant vectors [89, 90].
Replacingdefectivegenes(p53,BRCA1,RB,p16)
[35,38]
Genes that are mutated or deleted in cancer include
the cancer susceptibility genes p53 and BRCA1 [91]. Both
p53 and BRCA1 appear to inhibit cancer cells that lack
mutations in these genes, suggesting that the so-called
gene correction strategies may have broader potential
than initially believed [92]. p16, also called MTS1 (mul-
tiple tumor suppressive gene 1) is known to be an impor-
tant tumour suppressor gene especially in nonsmall cell
lung cancer [93]. Extensive eﬀort may have been put pre-
maturely into large scale phase III trials which in essence
conﬁrmedtheexcellenttoleranceofthesevectors,withlit-
tle clinical activity as single agents, strongly suggesting a
need for review of concept [94]. Over 900 patients have
been treated by gene transfer products (nonreplication-
selective AdV p53, Aventis Pharma) over a period of 5
years. Three phase II studies in patients with recurrent
squamous cell carcinoma of the head & neck testing dif-
ferent schedules and doses of administration resulted in
stable disease in 26% of patients (NDDO meeting report,
Valencia, Spain). No replication competent adenovirus
was detected.
Enzymesandprodrugs(TK)[95]
Genetic prodrug activation therapy depends on the
conditional expression of a gene encoding an enzyme ca-
pable of converting a nontoxic prodrug into an active
cytotoxic agent. An alternative strategy is to exploit the
transcriptional regulatory elements of genes that display
tumourselectivepatternsofexpression[44,96].Examples
of tissue speciﬁc patterns are those of MUC1, CEA, PSA,
thyroglobulin, and calcitonin whereas tumour selective
patterns include HER2 FGFR4 and VEGF [97]. In a phase
Iclinical trialof directintratumourinjection ofanHER2-
promoter-dependent cytosine deaminase (CD) plasmid
in patients with skin nodules of recurrent breast cancer,
restriction of cytosine deaminase expression to tumour
cells was documented. Combination of the MUC1 en-
hancer and HER2 promoters in pancreatic cancer that ex-
pressed both MUC1 and HER2 enhanced the level of ex-
pression as shown by cDNA microarray analysis. An ade-
noviral vector encoding the enzyme E.coli nitro-reductase
(NR) which reduces the prodrug CB1954 to a powerful
alkylating agent under the control of the CMV promoter
in primary and secondary liver cancer had some activity
in tumour cells which were resistent to Cisplatin. Synergy
was shown with Doxorubicin, Cisplatin and Topotecan
[98].
TK gene expression has been placed under the control
of the alpha-fetoprotein promoter to enhance speciﬁcity
for HCC cells and to diminish tk/gancyclovir toxicity to
normal cells. While 80% of animals died and 20% were
cured with the original vector, this modiﬁcation dramat-
ically increased survival and reduced treatment-related
toxicity.
PITFALLS IN GENE THERAPY / IMMUNOTHERAPY
OF CANCER
Diﬃculties encountered in clinical trial design using
biologicals are manifold, including the deﬁnition of opti-
mal dose, the absence of a correlation between maximally
tolerated dose (MTD) and maximal eﬃcacy, and the se-
quence and frequency of injections over time among oth-
ers. In addition, the frequently advanced disease stage of
patients under consideration means a vast heterogeneity
o ft u m o u rc e l l si st ob ee x p e c t e dw i t hah i g h l yv a r i a b l e
expression of tumour antigens by subclones. Moreover,
the heterogeneity of the genetic background in a patient
population may aﬀect the outcome and the usefulness of
a particular product may be diﬃcult to deﬁne in particu-
larsinceclinicalbeneﬁtisachievedonlyinasmallfraction
ofpatients.Prospectivestatisticalmethodologiesbasedon
MTD and clinical response are not optimal for making
decisions as to whether to develop or reject the gene ther-
apy product. Combinations with reference treatments ap-
pear to give added beneﬁt, but synchronising the timing
of injection of live viruses with potentially immune sup-
pressive chemotherapy, as well as uncertainty surround-
ing how to assess the relative contribution of each prod-
uct separately renders such combinations problematic. It
is also well documented that the immune system in late
stage disease is compromized, as evidenced by lymphope-
nia, low circulating CD4+ Tl y m p h o c y t e s ,a n daT h 2b i a s
in cytokine secretion, resulting in a less eﬃcacious im-
mune response.2003:1 (2003) Gene Therapy Applications to Cancer Treatment 41
Tcelldysfunction,defectivedendriticcellmaturation,
andinﬂammationincancerpatients
T-cell dysfunction in cancer patients has been classi-
ﬁed by 120 experts in the ﬁeld as the number-1 criteria
to be evaluated against clinical response. Hallmarks of T-
cell dysfunction are absent IFN-γ production, defective
T cell proliferative response, low and nonstimulable TCR
z chain expression, decreased signalling in T cells (Lck),
and low expression of nuclear transcription factors. Dys-
functional T cells appear to be provoked, at least in part,
through inadequate stimulation by immature DC [99],
lacking costimulatory molecule and CD40 ligand expres-
sion. It has been repeatedly demonstrated that tumour
culture supernatants contain elements which can inhibit
the functional maturation of DCs [1, 100, 101], and that
dendritic cells taken from patients with a variety of solid
tumours, including breast cancer, have an impaired abil-
ity to stimulate allogeneic T-lymphocytes. A number of
cytokines, such as IL-10 [102], IL-6 [103, 104], MCS-F
(CSF-1) [105]V E G F[ 106, 107, 108], and soluble IL-2
receptor [109], have been associated with immunosup-
pression and/or poor patient survival. M´ en´ etrier-Caux et
al [1] in a comparative study demonstrated that CSF-1
(macrophage colony stimulating factor) was the domi-
nant immuno-suppressive cytokine in renal cell cancer
cell lines. In particular, CSF-1 produced by renal cell car-
cinomacelllinesinhibitedthediﬀerentiationofDCsfrom
CD34+ progenitor cells, resulting instead in monocytic
cells with a potent phagocytic activity but lacking antigen
presentingfunction.Wewerefurtherabletoshowthatthe
CSF-1 induced reduction in allostimulatory function may
be mediated through an eﬀect on class-II traﬃc[ 110].
Clearly this has implications for immune based therapies.
Given its physiological role, CSF-1 is an obvious candi-
dateinthegenerationoftheseeﬀects.CSF-1expressionby
tumours is associated with extensive macrophage inﬁltra-
tionbothinanimal,andhumanmodels.Inarecentpubli-
cation, Lin et al [111] reported that CSF-1 is a critical fac-
tor in tumour progression and metastasis, an eﬀect medi-
ated through recruitment of inﬂammatory macrophages
to the tumour site. In a clinical gene therapy trial, using
VV-MUC1-IL-2 to treat patients with breast cancer, 2 out
of 4 patients with low CSF-1 serum levels and high CD4+
numbers at the start of treatment responded to therapy,
whereas none of the patients with high CSF-1 titers and
low CD4+ responded (submitted).
Anti-inﬂammatoryagentsincancerprevention
andtreatment
The link between chronic inﬂammation and the sub-
sequent development of cancer is well established, and
there is increasing evidence that these eﬀects are medi-
ated, at least in part, through the production of proin-
ﬂammatory cytokines and other mediators of inﬂamma-
tion [112]. Tumour cells, tumor associated macrophages,
tumour inﬁltrating lymphocytes, and the tumour stroma
itself, secrete factors such as TNF, VEGF, GM-CSF, IL-6,
and IL-10 which promote tumour progression. Eﬀects in-
clude angiogenesis, DNA damage, induction of T cell an-
ergy, production of proteases, and bypass of the tumour
suppressor protein p53 [113]. It is because of these delete-
rious eﬀects of inﬂammation on cancer pathogenesis that
researchers are increasingly looking for ways to modify
inﬂammation as part of cancer treatment. Breaking this
cycle of chronic inﬂammation and immune suppression
could thereby render existing therapies more eﬃcacious.
Mediators of inﬂammation implicated to date include
cyclo-oxygenase-2 (COX-2), which is highly induced in
many solid tumours [114, 115, 116, 117, 118, 119, 120]. A
role for this enzyme in tumour progression, angiogenesis,
andtheinhibitionofapoptosishasbeenestablishedinan-
imal models [121, 122]. Moreover, epidemiological stud-
ies have established that long-term intake of nonsteroidal
anti-inﬂammatory drugs (NSAIDs), which inhibit the en-
zymatic activity of COX-2, reduces the relative risk of de-
veloping colorectal cancer [123]. As a result their use as
adjuvant therapeutic agents in cancer clinical trials is cur-
rently under assessment.
NSAIDs also inhibit the expression of the nuclear
transcription factor NF-κB, which regulates activation
of speciﬁc genes encoding for diverse proteins involved
in the inﬂammatory response and the host immune
response. These include many diﬀerent cytokines and
chemokines, proteins involved in immune recognition,
proteins involved in the control of cellular proliferation
and apoptosis (c-IAP1, cIAP-2), and cell adhesion pro-
teins (ICAM-1). Through the regulation of genes encod-
ingformatrixmetalloproteinase9,tissueplasminogenac-
tivator, and ICAM-1, NF-κB may also play a role in tu-
mour metastasis. High levels of NF-κBh a v eb e e nd e m o n -
stratedinbothhaematologicalandsolidtumours,includ-
ing breast, ovarian, prostate, and colon cancers [124]. In
addition, preliminary results suggest that inhibition of
NF-κB in association with chemotherapy may be beneﬁ-
cial [125, 126].
FUTURE STRATEGIES FOR CANCER TREATMENT
IN PATIENTS
The need to develop adequate trial designs, to choose
precisely deﬁned endpoints, and to use methodologi-
cal strategies which compare favourably with established
reference treatments were recently emphasized by M.
Papaluca-Amati from the preauthorization unit at the
Agency for the Evaluation of Medicinal products for hu-
man use in Europe (EMEA). A major obstacle to the
pan European development of clinical gene therapy pro-
tocols is the multitude of national regulatory bodies and
the frequent requirement for translation into at least one
other language. Furthermore, according to Dr Papaluca-
Amati, common legislation is sometimes rendered prob-
lematicbytheclashbetweenSaxonandLatincultures,ex-
empliﬁed in the contrasting attitudes according to which
“what’s not forbidden is allowed for one, whilst what is
not allowed is forbidden for the other.”42 Susy M. Scholl et al 2003:1 (2003)
Futureclinicaltrialdesignandevaluationofgenetic
therapies
Gene therapy is still in its infancy, but signiﬁcant ac-
complishments have been achieved. The ability to trans-
fer genes safely and successfully into animals and patients
hasbeenestablishedandrapidlyexpandingpreclinicalev-
idence suggests that gene therapy will yet deliver on its
promise. So far clinical response to cancer vaccines has
been infrequent, but the ability to target tumour cells
speciﬁcally [127] together with interesting results using a
variety of vectors and transgenes in early tumour models
are intriguing.
Thefutureofcancertreatmentcouldlieincustomized
treatment [128], based on the molecular properties of
the tumour, utilizing combinations of novel and conven-
tional agents. The revolution in molecular methods has
allowed the development of approaches whereby cancer-
speciﬁcchangescanbetargeted,includingmutationcom-
pensation for correction of cancer-associated defects and
molecular chemotherapy for delivering toxic substances
and speciﬁc small molecular inhibitors of abnormally ac-
tivated pathways.
The choice of vector will depend on the result to be
achieved.Iftheexpectedresultisincreasedimmunogenic-
ity, then poxvirus or adenovirus vectors will be favoured.
If durable gene transfer is the goal, lentiviral vectors or
liposomal vectors are ideally suited. If selective targeting
for molecular chemotherapy or viral lytic agents are to
be used, selectively replicating adenoviruses are optimally
used. Tissue-speciﬁc promoters can be engineered into
the vector such that they will be expressed in the target
tissue.
The choice of the insert will depend on whether
correction of cancer-associated defects is molecular
chemotherapy for delivering toxic substances or an en-
hanced immune response against one or several speciﬁc
tumour antigens is to be engineered. In the latter case, it
wouldbeimportanttoknowwhethertumourMHCclass-
I expression is adequate or low (suggesting for instance
the need for IFN-γ transfer) and whether inﬂammatory
macrophages predominate over dendritic cells (suggest-
ing strategies to decrease inﬂammation). Synergy of vi-
ral vector-based approaches with standard therapies has
been documented by a number of authors and diagno-
sis and correction of cancer associated molecular defects
can enhance the eﬀectiveness of standard treatments. Be-
causep53statusinﬂuencestheexpressionofmicrotubule-
associated proteins and hence the sensitivity of a tumour
to taxanes, it is likely that p53 gene transfer could be use-
ful in taxane refractory patients [129]. Combinations of
standard therapies are extremely interesting in preclin-
ical studies and should ﬁnd their way into early clini-
c a ls t u d i e s[ 3, 130]. Ad-p53 transfer and Cisplatin ad-
ministration to GLC-82 cells exerted substantially greater
therapeutic eﬀects than the single agent treatment alone
[5]. Data from Nishizaki et al suggests that a combina-
tionofgenetherapy,chemotherapy,andradiationtherapy
may be an eﬀective strategy for human cancer treatment
[131].
Methodological aspects remain to be addressed; while
single agent phase I and phase II designs appear not to
be productive, the tolerance and the toxicity proﬁle of
combinations still need to be evaluated in the ﬁrst in-
stance. While the MTD is unlikely to be the most ac-
tive dose, it seems reasonable to test extremes of poten-
tially eﬀective dosages based on preclinical studies. A ﬂex-
ible design allowing progressive association with stan-
dard or third biological agents, based on preclinical re-
sults, should allow tolerance assessment and a subse-
quent increase in the number of patients creating a phase
II study if a real advantage is suggested. Multiple point
s u r v e y so fm o l e c u l a rm a r k e r sa tb a s e l i n ea n df o l l o w i n g
therapeutic interventions should shed light on the dy-
namic aspects of the tumour-host interactions. Finally,
the development of tools to evaluate tumour-induced
immune escape or drug resistance should be helpful in
curbing more advanced disease. A continuous interac-
tion with basic scientists involved in preclinical studies
should permit us to deﬁne RNA expression proﬁles pre-
dictive of a clinical response. Statistical innovations for
clinical trials include the minimax design [132] which as-
sures the patients safety while allowing ﬂexibility in the
study.
Immunological monitoring has recently been re-
viewed by a group of 120 experts in the ﬁeld [133]. The
frequent discrepancy between clinical and immunologi-
cal response in past trials was underlined and the advan-
tages and disadvantages of the diﬀerent methods (ease
of assay, precision of the test, reliability of the measure)
were commented upon. It is evident that immunological
response documentation is most relevant at the tumour
site as opposed to in peripheral PBMC and to this end,
noninvasive imaging of vectors and immune competent
cells might not be as futuristic as it ﬁrst sounds. In vac-
cine based therapies, a better deﬁnition of the patients’
genetic polymorphisms and immunological background
should narrow the predictive window for an eﬀective im-
mune response.
CONCLUSIONS
Rapid clinical advances in gene therapy of cancer are
to be expected. Progress will be achieved through the se-
lection of the most likely eﬀective therapy combinations
based both on the molecular analysis of tumours as well
as on preclinical studies aiming to correct given biological
defects. There is little doubt that we are at the beginning
of a new era in cancer treatment.
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